近日，中美华东的2类（含2.1、2.2）新药CMCY2304口崩片获批临床，公司的化药新药矩阵再添猛将。 2025年Q1-Q3在中国三大终端六大市场，中美华东跃升为化学药TOP12企业，销售额止跌大涨12.41%。 今年以来，公司陆续拿下了两个化药1类新药，目前化药2.2类新药依达拉奉片报产在审。 今年10月，中美华东接连拿下了两个化药1类新药，备受市场瞩目。 瑞玛比嗪注射液与经皮肾小球滤过率测量设备（TGFR）配合使用，用于评估患者的肾小球滤过率 （GFR），该产品（药+械）具备10亿元以上销售潜力。 马来酸美凡厄替尼片是一款新型、强效、高选择性、具有口服活性的不可逆EGFR/人表皮生长因子受 体-2（HER2）小分子抑制剂，凭借其差异化优势，也具备10亿元销售峰值的潜力。 今年7月，中美华东提交了2.2类新药依达拉奉片的上市申请，用于改善急性缺血性脑卒中（AIS）所致 的神经症状和功能障碍，提高日常生活能力。该产品不依赖专业医疗人员注射，患者可自行给药，并可 常温运输储存，具有更好的便利性和依从性，有望成为该治疗领域的潜力品种。 随着更多新药陆续上市，中美华东在10000亿化药市场的地位将进一步提升，结合 ...

近年来，一些人发现倒卖医保药品有利可图，就通过"医保取现""高价回收"等手段诱导参保人通过医保报销渠道获取的药品，再非法转手销售，流入市场， 这就是所谓的医保"回流药"。这种药不仅给用药人带来了直接的健康风险，还严重侵害了国家医保基金的安全。 通过医保取现 处方药遭非法倒卖 在江西景德镇，浮梁警方在一间民房内查获了1万多盒医保回收的处方药。视频中的画面是浮梁警方在一处黑窝点清点药品。站在民警身边的人，名为戴某 寿，这些药品正是他还没来得及出手的"医保回收药"。 江西景德镇市浮梁县公安局环食药侦大队副大队长 余冀文：非常震惊，我们这么多药品集中堆放在这里，我们现场清点出来了将近有1万多盒各类药品。 民房当仓库 各类处方药被随意堆放 经查实，警方在现场查获的这一万多盒药品均为正品，多为适用于透析治疗的肾病处方药，价格在几十元到上百元不等。那么，这些凭借医生处方才能购 买、使用的药品，为什么会数以万计地出现在这间民用房里呢？事情还要从警方接到的一起报案说起。 通过连日侦查，民警发现其中一间民用房多有蹊跷，院子中虽然摆放着大量茶叶包装的快递箱，可打包的人却从来没有拿过茶叶，而是常拿着药盒进出。租 赁这间房的是一名叫作 ...

Core Viewpoint - The National Medical Insurance Administration has reported five typical cases of individuals fraudulently obtaining medical insurance funds, highlighting serious issues of excessive drug purchases and collusion with "drug dealers" that undermine the integrity of the medical insurance system [1] Group 1: Case Summaries - Case 1: A resident of Lijiang, Yunnan, named Luo, fraudulently purchased and resold medications, causing a loss of 2.199 million yuan to the medical insurance fund from March 2021 to August 2023 [2] - Case 2: In Chongqing, two individuals, Song A and Song B, exploited their special disease insurance to excessively purchase and resell medications, resulting in a loss of 627,300 yuan since January 2023 [3] - Case 3: Zhang from Meishan, Sichuan, was found to have made excessive purchases across multiple medical institutions, leading to the dismantling of a large criminal gang and a recovery of 269,700 yuan for the medical insurance fund [4] - Case 4: Xu from Leqing, Zhejiang, was involved in fraudulent activities since 2016, leading to a loss of over 170,000 yuan, and was sentenced to three years in prison with a suspended sentence [5] - Case 5: Liu and three others in Ganzhou, Jiangxi, were found to have excessively purchased a specific medication, resulting in a loss of over 20,000 yuan, with ongoing investigations into the involved medical personnel [6][7] Group 2: Regulatory Actions - The National Medical Insurance Administration, in collaboration with judicial authorities, has taken strict actions against individuals involved in fraudulent activities, including criminal prosecutions and financial recoveries [1][7] - The cases reveal significant issues related to excessive drug purchases and the involvement of medical personnel, prompting the administration to adopt a "zero tolerance" policy towards fraud [7]

Core Points - Zhejiang Haizheng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the tacrolimus capsule, which has passed the consistency evaluation of generic drug quality and efficacy [1][2] Group 1: Drug Information - The drug name is tacrolimus capsule, available in dosages of 0.5mg and 1mg, classified as a chemical drug [1] - The original drug was developed by Astellas Pharma Co., Limited, and is primarily used to prevent organ rejection after liver or kidney transplants [2] - The global sales of tacrolimus capsules are projected to be approximately $138.73 million in 2024, with domestic sales around $46.16 million [2] Group 2: Company Impact - The approval of tacrolimus capsules for consistency evaluation is expected to enhance the company's market share and competitiveness in the pharmaceutical industry [3] - The company has invested approximately 61.44 million RMB in the consistency evaluation of this drug [2]

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for its Tacrolimus capsules, which have passed the consistency evaluation of quality and efficacy for generic drugs [2] Group 1 - The company announced the receipt of the "Drug Supplement Application Approval Notice" for Tacrolimus capsules [2] - The approval indicates that the company's Tacrolimus capsules have met the standards for quality and efficacy consistency as a generic drug [2]

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

Core Viewpoint - Haizheng Pharmaceutical has received approval from the National Medical Products Administration for its Tacrolimus Capsules, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - Haizheng Pharmaceutical's Tacrolimus Capsules are primarily used to prevent graft rejection after liver or kidney transplantation [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its Tacrolimus capsules, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tacrolimus capsules are primarily used for preventing graft rejection after liver or kidney transplantation [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its Tacrolimus capsules, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The company has been granted a "Drug Supplement Application Approval Notice" for Tacrolimus capsules by the National Medical Products Administration [1] - Tacrolimus capsules are primarily used to prevent graft rejection after liver or kidney transplants [1] - The original drug Tacrolimus capsules were developed by Astellas Pharma Co. Limited [1] Group 2: Market Context - The main domestic manufacturers of Tacrolimus capsules include Zhejiang Haizheng Pharmaceutical Co., Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [1]

Core Viewpoint - Huayi Taikang Pharmaceutical Co., Ltd. is progressing with its IPO guidance, with the guidance period set from April 1, 2025, to June 30, 2025, after starting the IPO filing on January 26, 2024 [2] Company Overview - Huayi Taikang was established in June 2010, focusing on the research, development, production, and sales of complex formulations and innovative formulations, providing one-stop, international pharmaceutical R&D and customized production services [3] - The company has a registered capital of 60.048 million yuan and is legally represented by Zhu Honggang [3] Product Portfolio - The main products approved for sale include sustained-release metoprolol succinate tablets, enteric-coated paroxetine sustained-release tablets, tacrolimus capsules, enteric-coated esomeprazole magnesium capsules, and agomelatine tablets, primarily used in treating hypertension, depression, organ transplantation, digestive system, and neurological diseases [4] Financial Performance - Revenue for Huayi Taikang from 2022 to 2024 was 113 million yuan, 258 million yuan, and 308 million yuan respectively, with net profits of -40.59 million yuan, 65.64 million yuan, and 59.40 million yuan [5] - In Q1 2025, the company reported revenue of 85.24 million yuan, a year-on-year increase of 30.41%, and a net profit of 28.46 million yuan, a year-on-year increase of 175.71% [6][8] - The basic earnings per share for Q1 2025 was 0.47 yuan, compared to 0.18 yuan in the same period last year [8]